1,438 reports of this reaction
5.0% of all DEXTROSE MONOHYDRATE reports
#1 most reported adverse reaction
MYELOSUPPRESSION is the #1 most commonly reported adverse reaction for DEXTROSE MONOHYDRATE, manufactured by BECTON DICKINSON AND COMPANY. There are 1,438 FDA adverse event reports linking DEXTROSE MONOHYDRATE to MYELOSUPPRESSION. This represents approximately 5.0% of all 28,872 adverse event reports for this drug.
Patients taking DEXTROSE MONOHYDRATE who experience myelosuppression should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MYELOSUPPRESSION is moderately reported among DEXTROSE MONOHYDRATE users, representing a notable but not dominant share of adverse events.
In addition to myelosuppression, the following adverse reactions have been reported for DEXTROSE MONOHYDRATE:
The following drugs have also been linked to myelosuppression in FDA adverse event reports:
MYELOSUPPRESSION has been reported as an adverse event in 1,438 FDA reports for DEXTROSE MONOHYDRATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
MYELOSUPPRESSION accounts for approximately 5.0% of all adverse event reports for DEXTROSE MONOHYDRATE, making it one of the most commonly reported side effect.
If you experience myelosuppression while taking DEXTROSE MONOHYDRATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.